Based on IHC staining for ESR, PGR, and HER2, the majority of breast cancer cases are classified as ER positive (~65%), followed by HER2 positive (~20%) and triple-negative breast cancers (TNBCs; ~15%) [2,3,4]. This evidence concerns the gene ERBB2 and breast carcinoma.